Hepatitis A/B vaccination of adults over 40 years old: Comparison of three vaccine regimens and effect of influencing factors

Vaccine

Volumn 24, Issue 26, 2006, Pages 5509-5515

  Van der Wielen, Marie ^a   Van Damme, Pierre ^a   Chlibek, Roman ^b   Smetana, Jan ^b   von Sonnenburg, Frank ^c  

^a WHO Collaborating Centre for Control and Prevention of Viral Hepatitis   (Belgium)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Elderly; Hepatitis A B vaccine; Influencing factors

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGE DISTRIBUTION; ANTIBODY RESPONSE; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VACCINATION;

ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS A VACCINES; HEPATITIS ANTIBODIES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; VACCINES, COMBINED;

EID: 33744793750     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.04.016     Document Type: Article

References (36)

1. http://www.who.int/mediacentre/factsheets/fs204/en/ accessed on 15 February 2006.
2. Andre F., Van Damme P., Safary A., and Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines 1 1 (2002) 9-23
3. Safary A., and Andre F. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 18 (2000) 57-67
4. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327 7 (1992) 453-457
5. Venters C., Graham W., and Cassidy W. Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines 3 2 (2004) 119-129
6. Van Damme P., Leroux-Roels G., Law B., Diaz-Mitoma F., Desombere I., Collard F., et al. Long-term persistence of antibodies induced by vaccination and safety follow-up with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 65 1 (2001) 6-13
7. Thoelen S., Van Damme P., Leentvaar-Kuypers A., Leroux-Roels G., Bruguera M., Frei P.C., et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 17 13-14 (1999) 1657-1662
8. Murdock G.L., Goa K., and Figgitt D.P. Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability. Drugs 63 23 (2003) 2625-2649
9. Van Damme P., and van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev Vaccines 3 3 (2004) 249-267
10. Stoffel M., Lievens M., Dieussaert I., Martin I., and Andre F. Immunogenicity of Twinrix in older adults: a critical analysis. Expert Rev Vaccines 2 1 (2003) 9-14
11. Roome A.J., Walsh S.J., Cartter M.L., and Hadler J.L. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 270 (1993) 2931-2934
12. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., and Margolis H. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 15 (1998) 1-8
13. Bock H.L., Kruppenbacher J., Sanger R., Hobel W., Clemens R., and Jilg W. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med 156 (1996) 2226-2231
14. Fisman D.N., Agrawal D., and Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Inf Dis 35 (2002) 1368-1375
15. Hess G., Hingst V., Cseke J., Bock H.L., and Clemens R. Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination. Eur J Clin Microbiol 11 (1992) 334-340
16. Honorati M.C., Mariani E., Dolzani P., and Facchini A. Biological parameters influencing the immunological response to plasma derived and recombinant hepatitis B vaccines. Ann Int Super Sanita 32 (1996) 369-374
17. Rendi-Wagner P., Kundi M., Stemberger H., Wiedermann G., Holzmann H., Hofer M., et al. Antibody response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 19 (2001) 2055-2060
18. Reuman P.D., Kubilis P., Hurni W., Brown L., and Nalin D. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 15 10 (1997) 1157-1161
19. Reutter J., Bart P.A., Francioli P., Safary A., and Frei P.C. Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/hepatitis B vaccination in 242 adult volunteers. J Viral Hepatitis 5 (1998) 205-211
20. Paganelli R., Scala E., Quinti I., and Ansotegui I.J. Humoral immunity in aging. Aging (Milano) 3 (1994) 143-150
21. Wick G., and Grubeck-Loebenstein B. The aging immune system: primary and secondary alterations of immune reactivity in the elderly. Exp Gerontol 32 (1997) 401-413
22. Ginaldi L., De Martinis M., D'Ostilio A., Marini L., Loreto M.F., and Corsi M.P. The immune system in the elderly. I. Specific humoral immunity. Immunol Res 20 (1999) 101-108
23. Treadwell T.L., Keeffe E.B., Lake J., Read A., Friedman L.S., Goldman I.S., et al. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med 95 6 (1993) 584-588
24. Wolters B., Junge U., Dziuba S., and Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 21 (2003) 3623-3628
25. Wiedermann G. Hepatitis A + B vaccine in elderly persons. J Travel Med 11 2 (2004) 130-132
26. Nothdurft H.D., Aumuller H., Aumuller R., Dames W., Stamer K., Kroetzsch H., et al. Letter to the editor. Vaccine 22 (2004) 592-593
27. Centres for Disease Control and Prevention (CDC): http://www.cdc.gov/nccdphp/dnpa/obesity/defining.htm.
28. ®) in adults. Vaccine 19 (2001) 4710-4719
29. Keystone J, Parsons J, Anstey R. Reactogenicity and immunogenicity of a combined vaccine against hepatitis A and B in older adults. In: Proceedings of the Ninth Triennal International Symposium on Viral Hepatitis, Liver Disease, Rome: C324, 21-25 April 1996.
30. American College of Physicians. General recommendations for adult immunization. In: American College of Physicians, ed. Guide for Adult Immunization. Philadelphia: American College of Physicians; 1989. p. 1-11.
31. American Academy of Pediatrics. Active and Passive Immunization. In: Peter G, editor, 1997 Red Book: Report of the Committee on Infectious Diseases, 24th ed., Elk Grove Village, IL: American Academy of Pediatrics; 1997. p. 1-71.
32. Jilg W. Intramuskuläre Injektion von Impfstoffen. Deutsche Medizinische Wochenschrift 118 (1993) 440
33. Ukena T., Esber H., Bessette R., Parks T., and Crocker B. Site of injection and response to hepatitis B vaccine. N Engl J Med 313 (1985) 579-580
34. Troisi C.L., and Hollinger F.B. Overview of clinical trials in low-endemic areas. In: Ellis R.W. (Ed). Hepatitis B vaccines in clinical practice (1993), Marcel Dekker Inc., New York-Basel-Hong Kong 179-208
35. Cockshott W.P., Thompson G.T., Howlett L.J., and Seeley E.T. Intramuscular or intralipomatous injections?. N Engl J Med 307 (1982) 356-358
36. Abraham B., Baine Y., De-Clercq N., Tordeur E., Gerard P.P., Manouvriez P.L., et al. Magnitude and quality of antibody response to a combination hepatitis A and hepatitis B vaccine. Antiviral Res 53 1 (2002) 63-73